Blog

March 23, 2022March 11, 2022

Beovu, a New Therapy for AMD, Funded for Use in Two Provinces

Novartis announced in December that a new anti-VEGF injection brolucizumab (brand name Beovu) is now funded by the Ontario and New Brunswick Drug Plans for treatment of wet age-related macular degeneration (AMD). Anti-VEGF injections are the standard of care for wet AMD, helping prevent further vision loss and in some cases restore some vision. Beovu is a new anti-VEGF that allows patients to delay the time between injections.

After the first few doses, eligible patients can be put on a once every three month treatment schedule. Novartis will be working with other provinces to increase access to this treatment for more Canadians.

March 22, 2022March 22, 2022

Neurolens Partners with University of Montreal’s Clinique Universitaire de la Vision

To fuel continued growth, Neurolens continues to invest heavily into developing new technologies and clinical research initiatives. A key driver of these initiatives is partnerships with leading schools of optometry such as the École d’optométrie de l’Université de Montréal. The two organizations will partner on several collaborative projects intended to define future product line enhancements and conceptualize product innovations, particularly in myopia control.

“We are thrilled and honored to partner with an institution with a well-known reputation for innovation like the École d’optométrie de l’Université de Montréal,” said Pierre Bertrand, CEO of Neurolens. “We are announcing a major donation of a 2nd generation Neurolens measuring device (NMD2) to the Clinique Universitaire de la Vision. This exciting partnership will help us define our innovation roadmap for years to come, and allow us to drive even more life-changing patient outcomes.”

“According to Dr. Langis Michaud, Optometrist and Director of the School of Optometry, “Innovation is in the DNA of our School. Considering the rapid changes we are subjected to, it is important to use the latest technology to help diagnose and treat visual anomalies. Neurolens’ major donation opens doors to innovative technologies that will benefit our patients. In addition, by developing a research partnership, we will be able to pool our strengths and develop products that will meet the visual needs of this technological age where children’s eyes are under great strain. We are excited to partner with Neurolens to fuel that will allow the industry to continue to adapt to the changing needs of patients worldwide.”

Click HERE for the full press release.

March 22, 2022March 22, 2022

Copenhagen Specs Kicks Off Optics and Eyewear Events for 2022

Forced to cancel the 2020 edition the day before its opening, Copenhagen Specs re-opened its doors on March 5 to rekindle the independent eyewear business in Northern Europe.

Its usual setting “Lokomotivværkstedet” – the centennial train repair building – hosted 53 exhibitors showcasing more than 85 innovative brands. 608 unique visitors from 16 different countries (Denmark, Sweden, Norway, Faroe Island, Iceland, Greenland, Finland, Poland, France, Germany, Italy, UK, Belgium, The Netherlands, Spain, and Switzerland), enjoyed the return of real interactions and have fully achieved their purchases goals, confirming Copenhagen Specs as the Scandinavian business hub.

CEO/Founder of Copenhagen Specs, Morten Gammelmark says: “It was such a joy finally being able to welcome the independent eyewear business to a Copenhagen Specs again after the period with cancelled tradeshows due to covid. But we could not succeed without the great support from the exhibitors and visitors, who stepped up and supported us. We are very grateful for that!”

Announced two years ago, the new Specs event is now on track. Independent eyewear will blossom in May in Spain. Barcelona Specs, May 7-8, 2022, will welcome eyewear lovers in a very cozy atmosphere at Fira Barcelona Montjuic in Barcelona city center.

Click HERE for the press release.

March 21, 2022March 11, 2022

Illusion Lite is Timeless

Certain designs never go out of style. Silhouette’s Illusion Lite model is the embodiment of this type of timeless style that is created from combining fresh ideas with classic looks. The temples of these glasses exude modern chic, while the fronts are more classic in style.

Featured model: Illusion Lite 1598

Distributed by COS: canadianoptical.com

March 18, 2022March 18, 2022

SightGlass Vision Joint Venture Begins Operation

EssilorLuxottica and CooperCompanies announce the finalization of their joint venture agreement for SightGlass Vision. This collaboration of two global vision care leaders accelerates the commercialization of novel spectacle lens technologies to expand the myopia management category.

SightGlass Vision’s Diffusion Optics Technology™ incorporates thousands of micro-dots into the lens that softly scatter light to reduce contrast on the retina, which is intended to reduce myopia progression in children.

“We are thrilled to see our joint venture with CooperCompanies come to life as SightGlass Vision begins to operate and the first products start to reach the market. Together with eye care professionals, we will be able to grow awareness about existing solutions and improve access to technologies that can help children today and in their future lives,” said Norbert Gorny, co-Chief Operating Officer at EssilorLuxottica.

“We are excited to begin this joint venture with EssilorLuxottica to grow the overall myopia management category. Adding spectacle lenses with SightGlass Vision technology to our portfolio of myopia management products translates into better eyesight and brighter lives for countless children. SightGlass Vision’s commitment to clinically based performance fits well with CooperVision, which has conducted the world’s longest-running myopia management clinical study and is committed to establishing myopia management as a standard of care for affected children,” said Dan McBride, Chief Operating Officer and General Counsel at CooperCompanies.

Click HERE for the full press release.